Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease
fey-tl kon-jen-i-tl hahy-per-troh-fik kahr-dee-oh-my-op-uh-thee due to gly-ko-jen stor-ij dih-zeez
Also known as: Infantile cardiac glycogenosis, Glycogen storage cardiomyopathy
At a Glance
What is Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease?
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease is a rare genetic disorder that affects the heart and its ability to function properly. It primarily impacts the cardiovascular system, leading to an abnormal thickening of the heart muscle. This condition is caused by mutations in genes responsible for glycogen metabolism, resulting in excessive glycogen accumulation in heart tissues. Over time, the heart's ability to pump blood effectively is compromised, leading to heart failure. Early symptoms may include difficulty breathing, poor feeding, and lethargy in infants, while late symptoms can progress to severe heart failure. Early diagnosis is critical as it allows for timely intervention and management, which can improve outcomes. The condition significantly impacts family life, requiring constant medical care and monitoring. The prognosis is generally poor, with many affected infants not surviving beyond the first year of life. Daily life for affected individuals involves frequent hospital visits and medical interventions. Families may need to make significant lifestyle adjustments to accommodate the care needs of the affected child. Genetic counseling is often recommended for families to understand the risks and implications of the disorder.
Medical Definition
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease is characterized by the pathological accumulation of glycogen within cardiac myocytes, leading to hypertrophy and impaired cardiac function. Histologically, the heart tissue shows vacuolated myocytes filled with glycogen deposits. This condition is classified under glycogen storage diseases, specifically affecting the heart. Epidemiologically, it is a rare disorder with a prevalence estimated at 1 in 100,000 live births. The disease course is typically rapid and progressive, often resulting in early infant mortality. Clinically, it presents with severe cardiac symptoms shortly after birth, necessitating immediate medical attention.
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hypertrophic cardiomyopathy manifests as thickening of the heart muscle, particularly the ventricles. This thickening is due to the accumulation of glycogen within the cardiac cells, leading to impaired cardiac function. Over time, the heart's ability to pump blood effectively diminishes, potentially resulting in heart failure. Patients may experience fatigue, shortness of breath, and reduced exercise tolerance, and management includes medications and lifestyle modifications to reduce cardiac workload.
Heart failure presents with symptoms such as shortness of breath, fatigue, and fluid retention. It occurs due to the heart's inability to pump blood efficiently as a result of structural changes and energy deficits in cardiac cells. As the condition progresses, symptoms worsen, leading to decreased quality of life and increased hospitalizations. Management includes medications like diuretics and ACE inhibitors, as well as lifestyle changes to manage symptoms and improve heart function.
Respiratory distress is characterized by difficulty breathing and rapid breathing rate. It is caused by the heart's inability to pump blood effectively, leading to fluid buildup in the lungs. Over time, this can result in chronic respiratory issues and increased susceptibility to infections. Patients may require supplemental oxygen and interventions to manage fluid overload and improve breathing.
Common
Muscle weakness is observed as reduced muscle strength and endurance. It results from glycogen accumulation in muscle tissues, impairing their function and energy production. The weakness can progress, affecting mobility and daily activities. Physical therapy and supportive care can help maintain muscle function and improve quality of life.
Feeding difficulties manifest as poor feeding, vomiting, and failure to thrive in infants. These issues arise due to the increased metabolic demands and energy deficits caused by cardiac dysfunction. Over time, inadequate nutrition can lead to growth delays and developmental issues. Nutritional support and feeding interventions are crucial to ensure adequate caloric intake and growth.
Hepatomegaly is the enlargement of the liver, often detected during physical examination. It occurs due to glycogen accumulation in liver cells, leading to liver dysfunction. As the condition progresses, liver function may become compromised, affecting metabolism and detoxification processes. Regular monitoring and supportive care are essential to manage liver-related complications.
Less Common
Arrhythmias are irregular heartbeats that can be detected during cardiac monitoring. They result from structural and electrical changes in the heart due to glycogen storage. Over time, arrhythmias can lead to palpitations, dizziness, and increased risk of cardiac events. Management includes medications and, in some cases, implantable devices to regulate heart rhythm.
Hypotonia is characterized by decreased muscle tone and floppiness. It is caused by impaired muscle function due to glycogen accumulation and energy deficits. This condition can affect motor development and lead to delays in reaching motor milestones. Early intervention with physical therapy can help improve muscle tone and support motor development.
What Causes Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease?
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease is primarily caused by mutations in the PRKAG2 gene located on chromosome 7q36.1. The PRKAG2 gene encodes the gamma 2-subunit of AMP-activated protein kinase (AMPK), a crucial energy sensor that regulates cellular energy homeostasis. Mutations such as the R531Q in PRKAG2 lead to constitutive activation of AMPK, disrupting normal energy sensing and glycogen metabolism. This results in excessive glycogen accumulation within cardiac myocytes, causing cellular hypertrophy and impaired cardiac function. The accumulation of glycogen disrupts normal organelle function, particularly affecting lysosomes and mitochondria, leading to cellular stress and apoptosis. Neighboring cells and tissues experience altered mechanical and electrical conduction properties, contributing to arrhythmias and cardiac dysfunction. Neuroinflammation and immune responses may be triggered by cellular damage, exacerbating tissue injury and fibrosis. White matter degeneration is not typically associated with this condition, but cardiac tissue undergoes structural remodeling. Symptoms appear in a pattern related to cardiac involvement, with early-onset hypertrophic cardiomyopathy and potential heart failure. Disease severity varies due to the specific mutation, genetic background, and environmental factors influencing metabolic pathways. The presence of additional mutations or polymorphisms in other genes may modify the clinical phenotype. Variability in enzyme activity levels and compensatory metabolic pathways also contribute to differences in clinical presentation. The interplay between metabolic derangements and cardiac structural changes dictates the progression and severity of symptoms. Early diagnosis and intervention are crucial in managing disease progression and improving outcomes.
How is Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in the neonatal period or early infancy when symptoms such as cardiomyopathy and muscle weakness become apparent. Infants may present with signs of heart failure, respiratory distress, or hypotonia. Early recognition is crucial due to the rapid progression of the disease. A detailed family history and clinical suspicion guide the initial diagnostic approach.
Clinicians look for signs of heart failure, such as tachypnea, hepatomegaly, and poor feeding. A detailed family history of metabolic or genetic disorders is crucial. Physical examination may reveal a heart murmur, hypotonia, or muscle weakness. This step helps determine the need for further specialized testing and referral to a geneticist.
Echocardiography is the primary imaging modality used to assess cardiac structure and function. It reveals hypertrophic cardiomyopathy with thickened ventricular walls and potential outflow tract obstruction. These findings confirm the presence of structural heart disease and help exclude other causes of cardiomyopathy. Differential diagnoses such as congenital heart defects or other cardiomyopathies are considered based on imaging results.
Specific tests include serum creatine kinase and liver function tests to assess muscle and liver involvement. Elevated biomarkers such as creatine kinase indicate muscle damage, while abnormal liver enzymes suggest hepatic involvement. Abnormal results prompt further metabolic testing, including enzyme assays. These results guide the decision to pursue genetic testing and metabolic workup.
Genetic testing involves sequencing genes such as PRKAG2 and others associated with glycogen storage diseases. Mutations like the R531Q in the gamma 2-subunit of AMP-activated protein kinase are identified. These results confirm the diagnosis of glycogen storage disease-related cardiomyopathy. Genetic findings inform family counseling regarding recurrence risk and potential prenatal testing.
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease Treatment Options
Beta-blockers are used to manage hypertrophic cardiomyopathy by reducing heart rate and myocardial oxygen demand. Drugs such as propranolol and atenolol are commonly used. Clinical evidence suggests they can improve symptoms and exercise tolerance. However, their efficacy is limited in severe cases, and side effects may include hypotension and bradycardia. Regular monitoring is necessary to adjust dosages and assess response.
Techniques include aerobic exercises tailored to the child's tolerance and physical condition. The goal is to improve cardiovascular fitness and muscle strength. Sessions are typically conducted 2-3 times a week for several months. Outcomes are measured by improved exercise capacity and quality of life. Long-term benefits include enhanced physical endurance and reduced cardiac symptoms.
Indicated for severe outflow tract obstruction not responsive to medical therapy. The procedure involves surgical removal of part of the thickened septal wall to relieve obstruction. Expected benefits include improved cardiac output and symptom relief. Surgical risks include arrhythmias and potential need for pacemaker implantation. Post-operative care involves intensive monitoring and gradual reintroduction of physical activity.
The care team includes cardiologists, geneticists, dietitians, and physical therapists. Interventions focus on optimizing cardiac function, nutritional support, and physical therapy. Psychosocial support strategies involve counseling and support groups for families. Family education covers disease management, emergency planning, and genetic implications. Long-term monitoring involves regular follow-ups to assess disease progression and treatment efficacy.
When to See a Doctor for Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease
- Severe shortness of breath — this may indicate heart failure and requires immediate medical attention.
- Sudden loss of consciousness — could be a sign of a serious cardiac event.
- Chest pain or pressure — may indicate a heart attack or other serious cardiac issue.
- Persistent fatigue — could suggest worsening cardiac function and should be evaluated by a doctor.
- Swelling in the legs or abdomen — may indicate fluid retention due to heart failure.
- Rapid or irregular heartbeat — can be a sign of arrhythmia and needs medical assessment.
- Mild fatigue — monitor energy levels and ensure adequate rest.
- Occasional palpitations — keep track of frequency and duration, and consult a doctor if they worsen.
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease — Frequently Asked Questions
Is this condition hereditary?
Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease can be inherited in an autosomal recessive or dominant pattern. The probability of passing it to children depends on the specific genetic mutation involved. De novo mutations can occur, meaning the condition can appear without a family history. Carrier status can have implications for family planning, as carriers may pass the gene to offspring. Genetic counseling is recommended for affected families to understand inheritance patterns and risks.
What is the life expectancy for someone with this condition?
Life expectancy varies significantly depending on the age of onset and severity. Early onset, especially in infancy, often leads to a poorer prognosis due to rapid disease progression. Mortality is typically caused by heart failure or arrhythmias. Treatment can improve quality of life and may extend survival, but outcomes are highly variable. Realistic expectations should be discussed with a healthcare provider, considering individual circumstances.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, imaging studies, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as cardiologists and geneticists are typically involved in the diagnostic process. Delayed diagnosis may occur due to symptom overlap with other conditions. Genetic testing confirms the diagnosis by identifying specific mutations.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and enzyme replacement therapies showing promise. Novel approaches aim to address the underlying genetic causes of the disease. ClinicalTrials.gov is a resource for finding current trials, and patients should discuss potential participation with their doctor. It's important to ask about the risks and benefits of new treatments. The timeline for new treatments becoming widely available can be uncertain and lengthy.
How does this condition affect daily life and activities?
This condition can significantly impact mobility and self-care, especially in severe cases. Educational accommodations may be necessary due to physical limitations. Social and emotional challenges are common, requiring support from family and peers. The condition can place a significant burden on families, necessitating access to resources and support networks. Adaptive equipment and therapies can help improve quality of life.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Infantile-onset Pompe disease with neonatal debut: A case report and literature review.
Martínez M, Romero MG, Guereta LG et al. · Medicine (Baltimore) · 2017 · PMID: 29390460
- 2.Pathogenesis of cardiac conduction disorders in children genetic and histopathologic aspects.
Gilbert-Barness E, Barness LA · Am J Med Genet A · 2006 · PMID: 16969859
- 3.Review: Metabolic cardiomyopathy and conduction system defects in children.
Gilbert-Barness E · Ann Clin Lab Sci · 2004 · PMID: 15038665
- 4.Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency.
Regalado JJ, Rodriguez MM, Ferrer PL · Pediatr Cardiol · 1999 · PMID: 10368461
- 5.Pulmonary interstitial glycogenosis associated with pulmonary hypertension and hypertrophic cardiomyopathy.
Alkhorayyef A, Ryerson L, Chan A et al. · Pediatr Cardiol · 2013 · PMID: 22453840
- 6.Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency.
Burwinkel B, Scott JW, Bührer C et al. · Am J Hum Genet · 2005 · PMID: 15877279
- 7.A rare presentation of Pompe disease with massive hypertrophic cardiomyopathy at birth.
Noori S, Acherman R, Siassi B et al. · J Perinat Med · 2002 · PMID: 12530110
- 8.Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase.
Akman HO, Sampayo JN, Ross FA et al. · Pediatr Res · 2007 · PMID: 17667862
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-04-27